Roche Strikes Cancer Drug Deal With China's Hansoh Worth Over $15 Billion
The Swiss pharmaceutical company will receive $400 million upfront while the Chinese firm retains rights in mainland China and other regions.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
The story so far
2 publishers have covered this in 4 articles since 19 Oct 2026. Quartz published first, on 19 October at 12:40 UTC; STAT followed 44 min later. The most recent article, from STAT, appeared on 20 October at 16:42 UTC.
Outlets reporting it: Quartz, STAT.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
- QuartzRoche struck a cancer drug licensing deal with China's Hansoh that could exceed $15 billion
- QuartzRoche hat einen Lizenzvertrag für Krebsmedikamente mit dem chinesischen Unternehmen Hansoh abgeschlossen, der mehr als 15 Milliarden Dollar wert sein könnte.
- STATSTAT+: Pharmalittle: We’re reading about Roche investments in Germany, a Gilead bowel disease drug, and more
- STATSTAT+: Roche continues to look to China for new drugs
Sources
Every article we clustered into this story. Headlines link to the publisher.
- STAT+: Roche continues to look to China for new drugs STAT
- STAT+: Pharmalittle: We’re reading about Roche investments in Germany, a Gilead bowel disease drug, and more STAT
- Roche struck a cancer drug licensing deal with China's Hansoh that could exceed $15 billion Quartz
- Roche hat einen Lizenzvertrag für Krebsmedikamente mit dem chinesischen Unternehmen Hansoh abgeschlossen, der mehr als 15 Milliarden Dollar wert sein könnte. Quartz
In this story
- Roche
- Hansoh